eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2023
vol. 48
 
Share:
Share:
abstract:
Clinical immunology

COVID-19 vaccination in healthcare workers: Long-term benefits and protection

Joanna Szczepanek
1
,
Monika Skorupa
1, 2
,
Joanna Jarkiewicz-Tretyn
3
,
Andrzej Tretyn
1, 2

  1. Centre for Modern Interdisciplinary Technologies, Nicolaus Copernicus University, Torun, Poland
  2. Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University, Torun, Poland
  3. Non-Public Health Care Centre, Cancer Genetics Laboratory, Torun, Poland
Cent Eur J Immunol 2023; 48 (4): 311-321
Online publish date: 2024/01/10
View full text Get citation
 
PlumX metrics:
Introduction:
This study aimed to evaluate the long-term effectiveness of COVID-19 vaccination in healthcare workers by analyzing the population’s response to the vaccine after two years, based on anti-SARS-CoV-2 protein S antibody levels. Additionally, the study aimed to assess the impact of basic factors on antibody levels.

Material and methods:
A total of 4,090 healthcare workers were included in the study, and their antibody levels were measured using ELISA to detect anti-SARS-CoV-2 immunoglobulin G (IgG). Statistical analysis was conducted to examine the influence of COVID-19 infection, vaccination status, and number of vaccine doses on antibody concentrations.

Results and Conclusion:
The majority of participants (85.1%) received the Pfizer/BioNTech vaccine, while a smaller percentage chose vector vaccines such as AstraZeneca and Johnson & Johnson. The incidence of COVID-19 among vaccinated individuals was relatively low for all vaccines, confirming their effectiveness in preventing symptomatic SARS-CoV-2 infection. The study observed variations in IgG antibody levels within the study population, with only 0.46% of individuals testing negative for the presence of antibodies. The average anti-SARS-CoV-2 IgG values showed significant differences across consecutive 3-month periods following infection or vaccination, with a gradual decrease over time. Notably, the most significant changes in antibody levels were observed within the first 6 months (mean values ranged from 3647.11 BAU/ml to 2601.49 BAU/ml). Subsequently, minor fluctuations were observed, with mean antibody values hovering around 2000 BAU/ml. The differences between average anti-SARS-CoV-2 IgG values between consecutive 3-month periods from disease onset were statistically significant.

keywords:

protection, immunity, vaccine efficacy, antibody response, herd immunity, pandemic, SARS-CoV-2

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.